On Friday, Following Stocks were among the “Top 100 Gainers” In U.S. Stock Exchange: Cosan (NYSE: CZZ), AEterna Zentaris (NASDAQ:AEZS), Avid Technology, (NASDAQ:AVID), Vanguard Natural Resources, LLC (NASDAQ:VNR)
Cosan Limited (USA) (NYSE: CZZ) rose 5.31%, and closed at $6.55. The stock has the beta value of 1.94, and its volatility for the week is 6.20%, while for the month it is 4.23%. The company has the market capitalization of $1.77 billion. The company holds the book value per share of 7.48, whereas cash per share is 1.73. Price to book ratio remained 0.88, while price to sale ratio is 0.63. Analysts mean recommendation for the stock is said to be 1.70 (where 1=Buy, 5=sale).
Cosan Limited (USA) (CZZ) along with its subsidiaries, holds in sugar and ethanol, fuel, logistics services, lubricants, and piped natural gas businesses primarily in Brazil, rest of South America, Europe, the Middle East, Asia, and North America. The companys Raízen Energia segment produces and markets various products derived from sugar cane, including raw sugar, and anhydrous and hydrated ethanol.
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) enhanced 5.26%, and closed at $0.600. The company holds the market capitalization of $54.12M. For the last twelve months, the stock was able to keep return on equity at -136.10%, while return on assets at –30.20%. Its 20-day moving average decreased -0.29%, below 50-day moving average of 4.52%, below 200-day moving average of -35.90% from the latest market price of $0.60. The mean recommendation of analysts for this stock is 2.50. (Where 1=Buy, 5=Sale).
AEterna Zentaris Inc. (USA) (AEZS) a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women’s health. The company’s product pipeline includes MACRILEN, which completed the Phase 2 trial for use in the diagnosis of adult growth hormone deficiency; and zoptarelin doxorubicin, which is in Phase 3 clinical study zoptarelin doxorubicin in endometrial cancer (ZoptEC) of the compound in women with advanced, recurrent, or metastatic endometrial cancer.
Avid Technology, Inc. (NASDAQ:AVID) uncovered that M6 Group, the media company behind the most profitable national television network in France, has embraced Avid EverywhereTM and implemented a cutting-edge Avid media asset management solution for managing content and media assets. The new Avid workflow enables M6 to share purchased content between 50 users and four departments, enhance collaboration between team members, save time and resources throughout the organization, and maximize the value of its massive archive of media assets.
Avid Technology, Inc. (NASDAQ:AVID) inclined 5.26%, and closed at $15.02. The company has the market capitalization of $592.78 million. The beta value of the stock is 1.53. On the other hand the stock’s volatility for the week is 10.32%, and for the month is 5.31%. The stock’s price to sale ratio is $1.12. Analyst’s mean recommendation regarding this stock is 1.50. (Where 1=Buy, 5=Sale).
Avid Technology, Inc. (AVID) develops, markets, sells, and supports software and hardware for digital media content production, management, and distribution in the United States, the other Americas, Europe, the Middle East, Africa, and the Asia-Pacific.
Vanguard Natural Resources, LLC (NASDAQ:VNR) has disclosed a cash distribution attributable to the month of February 2015 of $0.1175 per unit ($1.41 on an annual basis) payable on April 14, 2015 to unitholders of record on April 1, 2015. Vanguard has also declared cash distributions for its 7.875% Series A Cumulative Redeemable Perpetual Preferred Units (VNRAP) of $0.1641 per unit, its 7.625% Series B Cumulative Redeemable Perpetual Preferred Units (VNRBP) of $0.15885 per unit, and its 7.75% Series C Cumulative Redeemable Perpetual Preferred Units (VNRCP) of $0.16146 per unit, all payable on April 15, 2015 to unitholders of record on April 1, 2015.
Vanguard Natural Resources, LLC (NASDAQ:VNR)’s shares picked up 5.21%, and closed at $14.75. The stock volatility for the week is 5.56%, while for the month remained 5.00%. The company holds consensus target price of $17.42.
If we consider EPS growth of the company, then the company indicated the following observations:
The company showed 0.56 diluted EPS growth for trailing twelve months. However, YTD EPS growth remained -28.20% and Annual EPS growth for the past 5 years is considered as 15.80%.
The mean recommendation of analysts for this stock is 2.60. (Where 1=Buy, 5=Sale).
Vanguard Natural Resources, LLC (VNR) along with its subsidiaries acquires and develops oil and natural gas properties in the United States. It owns properties, and oil and natural gas reserves primarily located in nine operating basins, including the Arkoma Basin in Arkansas and Oklahoma; the Permian Basin in West Texas and New Mexico; the Big Horn Basin in Wyoming and Montana; the Piceance Basin in Colorado; the Gulf Coast Basin in Texas, Louisiana, and Mississippi; the Wind River Basin in Wyoming; the Williston Basin in North Dakota and Montana; the Green River Basin in Wyoming; and the Powder River Basin in Wyoming
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
